Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial

doi:10.3748/wjg.v32.i14.116529

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 14

This Article

(42)

(37)

(0)

(24)

(1)

(1180)

(1)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Apr 14, 2026; 32(14): 116529
Published online Apr 14, 2026. doi: 10.3748/wjg.v32.i14.116529

Table 2 The efficacy of thalidomide on hemorrhagic chronic radiation proctitis as measured by the Subjective Objective Management Analysis system score

		Pre-treatment				Post-treatment
SOMA effect	62	1	2	3	4	0	1	2	3	4
Completely remitted	6	0	0	2	4	6	0	0	0	0
Alleviative	46	0	2	25	19	0	27	14	5	0
Unchanged	7	0	2	4	1	0	0	2	4	1
Aggravated	3	0	2	1	0	0	0	0	1	2
Efficacy rate (%)	83.9%

SOMA: Subjective Objective Management Analysis system.

Full Size Table

Citation: Huang XY, Zhong QH, Kuang YY, Li ZJ, Huang BJ, He YJ, Zhu MM, Guan Q, Li XY, Qin QY, Ma TH. Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial. World J Gastroenterol 2026; 32(14): 116529
URL: https://www.wjgnet.com/1007-9327/full/v32/i14/116529.htm
DOI: https://dx.doi.org/10.3748/wjg.v32.i14.116529

Huang XY, Zhong QH, Kuang YY, Li ZJ, Huang BJ, He YJ, Zhu MM, Guan Q, Li XY, Qin QY, Ma TH. Thalidomide for refractory hemorrhagic chronic radiation proctitis secondary to pelvic malignancy radiotherapy: A phase II clinical trial. World J Gastroenterol 2026; 32(14): 116529 [DOI: 10.3748/wjg.v32.i14.116529]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.